Subscribe To
Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy<...
June 10, 2023, 2:47 pm
Why shares of day one pharmaceuticals are up monday
Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive p...
June 5, 2023, 12:30 pm
Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...
June 3, 2023, 6:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...
May 25, 2023, 9:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...
May 25, 2023, 9:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...
May 25, 2023, 5:15 pm
Molecular partners to present positive data from ongoing phase 1 trial of mp0317 (fap x cd40) monotherapy in patients with advanced solid tumors at the 2023 asco annual meeting
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation...
May 25, 2023, 5:01 pm
Cullinan oncology to present first monotherapy clinical data for cln-619, a novel anti-mica/b antibody, at asco 2023
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose ca...
May 25, 2023, 5:00 pm
Geron's data allows development of several catalysts
Primary endpoint of 8-week transfusion independence met in the phase 3 IMerge study; Imetelstat was used as a ...
January 9, 2023, 7:01 pm
Applied molecular transport announces top-line phase 2 results from lombard monotherapy trial of oral amt-101 in patients with moderate-to-severe ulcerative colitis
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to pla...
December 22, 2022, 10:30 pm
Agenus: advancement of botensilimab could create a great pivot point
Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy again...
December 13, 2022, 5:57 am
Vincerx pharma presents preclinical data on vip943 in acute myeloid leukemia models at the 64th american society of hematology annual meeting 2022
Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with sign...
December 11, 2022, 3:05 pm
Fate therapeutics highlights ipsc-derived, off-the-shelf car nk cell programs for multiple myeloma at 2022 ash annual meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as ...
December 10, 2022, 7:46 pm
Rapt therapeutics presents update from its phase 1/2 clinical trial for flx475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer
Data Presented at ESMO Immuno-Oncology Congress SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT)...
December 8, 2022, 11:30 am
Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...
November 30, 2022, 7:05 pm
Achilles therapeutics to present early proof of concept of safety and clinical activity of clonal neoantigen reactive t cells at the esmo immuno-oncology annual congress 2022
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT ...
November 30, 2022, 6:05 pm
Rbc says verastem interim analysis in ovarian cancer reinforces enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 progr...
June 7, 2022, 2:35 pm
Curis shares gain on encouraging data presentation from blood cancer trials at asco meeting
Curis Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical On...
June 6, 2022, 8:01 am
Immunogen's stock is up 12% after the fda accepts application for new ovarian-cancer therapy
Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an ...
May 23, 2022, 7:59 am